Humana (HUM) Stock Price, Fundamentals & Analysis

What HUM does

Humana (HUM) is a US stock in the Healthcare sector, specifically Healthcare Plans. Headquartered in Louisville, United States, it provides medical and specialty insurance products across two segments: Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage plans, stand-alone prescription drug products, Medicare supplements, and specialty insurance such as dental, vision, life, and disability, along with administrative services for military personnel and their dependents. The CenterWell segment operates senior-focused primary care centers, a management services organization, a home health provider, and a pharmacy and hospice solutions business. Humana is part of the S&P 500 and operates alongside peers such as Cencora (COR), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Stryker Corporation (SYK), Moderna (MRNA), Henry Schein (HSIC), and Medtronic (MDT).

Key numbers explained

• The current price of 374,78 USD reflects the latest trading value; a +0,75% change today indicates a modest intraday move.
• The trailing P/E ratio of 36,1 shows how much investors pay per dollar of past earnings, while the forward P/E ratio of 22,6 uses expected future earnings and is typically read as a more optimistic valuation gauge.
• The dividend yield of 0,95% represents the annual dividend as a percentage of the share price, with an ex-dividend date of 30 oct. 2026 marking the cutoff for eligibility.
• A beta of 0,75 suggests the stock has historically moved less than the overall market, which is typical for large healthcare companies.
• The 52-week range of 163,11 – 428,88 shows the lowest and highest prices over the past year, with the current price near the middle of that span.
• Revenue growth of 26,2% year over year indicates strong top-line expansion, while a profit margin of 0,9% and operating margin of 3,5% highlight the tight cost structure typical of the industry.

Recent news

Recent headlines cover topics such as the financial case for healthsharing models, analysis of UnitedHealth's stock trajectory, a distribution agreement between TempraMed and CenterWell Pharmacy, and broader questions about earnings growth and AI-driven cost management in healthcare. Other stories examine margin dynamics for CVS and Aetna, reflecting ongoing investor focus on competitive positioning and cost pressures across the sector.

What to watch

Investors tracking Humana typically monitor regulatory changes affecting Medicare Advantage and prescription drug coverage, as well as shifts in healthcare policy and reimbursement rates. Broader factors include industry competition, drug pricing trends, and the performance of peers such as Cencora (COR) and Gilead Sciences (GILD), which can influence sentiment across the healthcare plans space.